Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Market Cap	13.33B +12.9%
Revenue (ttm)	519.61M +49.9%
Net Income	-1.23B
EPS	-8.13
Shares Out	157.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364,844
Average Volume	218,807
Open	85.70
Previous Close	85.50
Day's Range	84.20 - 87.60
52-Week Range	57.70 - 93.70
Beta	0.70
RSI	59.32
Earnings Date	Feb 24, 2026

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2024, Foresee Pharmaceuticals's revenue was 418.69 million, an increase of 114.67% compared to the previous year's 195.04 million. Losses were -1.08 billion, 4.32% more than in 2023.